목차

논문요약············································································1
Ⅰ. 서론·············································································3
Ⅱ. 재료 및 방법 ·································································5
1. 재료············································································5
1)세포 ···········································································5
2)약재 ···········································································5
3)동물 및 사료··································································5
4)시약 ···········································································6
5)기기 ···········································································7
2. 방법············································································7
1)시료 추출 ····························································7
2)RAW 264.7 cell의 배양······················································7
3)세포독성 ······································································8
4)항산화 효능··················································8
(1) DPPH radical 소거능 측정 ············································8
5)항염증 효능······················································8
(1) NO 측정································································9
(2) PGE2 측정·······························································9
(3) Cytokine 측정····························································9
6)경골 골절 유발 ·····························································10
7)그룹 배정 및 시료 처리 ··················································10
8)혈청 분리 ···································································11
9)골절유합 관련 인자 측정··················································11
(1) Osteocalcin 측정·······················································11
(2) Calcitonin 및 CTXⅡ측정·············································11
(3) TGF-β 및 BMP-2 측정··············································12
10)방사선 검사·································································12
3. 통계처리······································································12
Ⅲ. 결과·········································································14
1. 안전성 ·························································14
1) RAW 264.7 cell에 대한 세포 독성·····································14
2. 항산화 효능 ···································································16
1) DPPH radical 소거능 ···················································16
3. 항염증 효능·································································18
1) NO 생성량·································································18
2) PGE2 생성량······························································20
3) Cytokine 생성량··························································22
(1) IL-1β···································································22
(2) IL-6·····································································24
(3) TNF-α·································································26
4. 골절유합 관련 인자 측정··················································28
1) Osteocalcin 생성량·······················································28
2) Calcitonin 생성량·························································30
3) CTXⅡ 생성량····························································32
4) TGF-β 생성량····························································34
5) BMP-2 생성량····························································36
5. 방사선 소견·································································38
Ⅳ. 고찰·········································································41
Ⅴ. 결론·········································································49
참고문헌·······································································51